We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Paper-Based Microneedle Skin Patch for Continuous Glucose Monitoring

By LabMedica International staff writers
Posted on 23 Sep 2020
A microneedle skin patch for the continuous monitoring of an individual’s glucose level was designed to be a painless and disposable screening and diagnostic test for diabetes patients, as well as those with pre-diabetes.

Porous microneedles are expected to have a variety of potential applications in diagnostics owing to their ability to penetrate human skin painlessly and extract bio‐fluid by capillary action. More...
Investigators at the University of Tokyo (Japan) have applied this technology for screening and monitoring levels of glucose.

The microneedles were fabricated by pouring a mixture of a melted biodegradable polymer and salt into the cone-shaped cavities of a micro-mold while applying heat. The mold was then inverted with the needles on the lower side, and the device was placed on top of a sheet of paper with high pressure applied from above. The high pressure forced the polymer mixture into the pores of the paper, securing the attachment and allowing fluid drawn through the needles to pass effortlessly into the paper. After removal from the mold, the needles were cooled in a solution that removed the salt, leaving behind pores, through which fluid could flow into the paper. A paper glucose sensor was then attached to the paper base of the needle array. The final product was disposable and biodegradable, and its use did not require any medical expertise or training.

The paper‐based glucose sensor was used to demonstrate the absorption property of the microneedles, and showed successful sample extraction and glucose concentration analysis from agarose gel‐based skin mimics. The investigators maintained that the platform had the potential to integrate various different paper‐based bio‐sensors in order to function as painless and disposable rapid screening and diagnostic tests for many metabolites.

"We have overcome this problem by developing a way to combine porous microneedles with paper-based sensors," said senior author Dr. Beomjoon Kim, professor in the institute of industrial science at the University of Tokyo. "The result is low-cost, disposable, and does not require any additional instruments."

The microneedle device was described in the August 2020 issue of the journal Medical Devices & Sensors.


Related Links:
University of Tokyo


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.